Apeiron Investment Group, angel investor Peter Thiel, and Catalio Capital Management have led a $125m series-C round for Germany-based psychedelic and non-psychedelic mental health therapy compounds developer Atai Life Sciences.
Parent company Reiff Group said in a statement that the sale is part of its ongoing realignment plan
Neil Bennett, previously of Beacon Rail Leasing, will be appointed executive chairman of the company
Healthtech-focused VC sees oppprtunities in the developing European market, managing director Christian Weiß tells Unquote
Paul Keen, previously CFO of ETC Venues, will join the board as a non-executive director